NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)
| dc.contributor.author | McNamara, Mairead G | |
| dc.contributor.author | Goyal, L. | |
| dc.contributor.author | Doherty, M. | |
| dc.contributor.author | Springfeld, C. | |
| dc.contributor.author | Cosgrove, D. | |
| dc.contributor.author | Sjoquist, K. M. | |
| dc.contributor.author | Park, J. O. | |
| dc.contributor.author | Verdaguer, H. | |
| dc.contributor.author | Braconi, C. | |
| dc.contributor.author | Ross, P. J. | |
| dc.contributor.author | Gramont, A. | |
| dc.contributor.author | Zalcberg, J. R. | |
| dc.contributor.author | Palmer, D. H. | |
| dc.contributor.author | Valle, Juan W | |
| dc.contributor.author | Knox, J. J. | |
| dc.date.accessioned | 2020-06-16T11:03:11Z | |
| dc.date.available | 2020-06-16T11:03:11Z | |
| dc.date.issued | 2020 | en |
| dc.identifier.citation | M. G. McNamara, L. Goyal, M. Doherty et al. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncol. 2020;16(16):1069-1081. | en |
| dc.identifier.pmid | 32374623 | en |
| dc.identifier.doi | 10.2217/fon-2020-0247 | en |
| dc.identifier.uri | http://hdl.handle.net/10541/623012 | |
| dc.description.abstract | Gemcitabine/cisplatin is standard of care for first-line treatment of patients with advanced biliary tract cancer (aBTC); new treatments are needed. NUC-1031 is designed to overcome key cancer resistance mechanisms associated with gemcitabine. The tolerability/efficacy signal of NUC-1031/cisplatin in the Phase Ib ABC-08 study suggested that this combination may represent a more efficacious therapy than gemcitabine/cisplatin for patients with aBTC, leading to initiation of the global NuTide:121 study which will include 828 patients /=18 years with untreated histologically/cytologically-confirmed aBTC (including cholangiocarcinoma | en |
| dc.language.iso | en | en |
| dc.relation.url | https://dx.doi.org/10.2217/fon-2020-0247 | en |
| dc.title | NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121) | en |
| dc.type | Article | en |
| dc.contributor.department | Division of Cancer Sciences, The University of Manchester & The Christie NHS Foundation Trust, Manchester, | en |
| dc.identifier.journal | Future Oncology | en |
| dc.description.note | en] |